Akero Therapeutics, Inc. - Common Stock (AKRO)

The biotech will soon have a new owner.

Novo Nordisk to buy Akero Therapeutics for up to $5.2 billion, adding EFX, a late-stage MASH treatment candidate, to its metabolic disease portfolio.

The deal follows Roche's plan to buy 89bio, another MASH-focused biotech company.

Novo Nordisk is set to acquire the firm, and Akero’s shareholders will receive $54 per share in cash at closing in addition to a contingent value right.

Akero Therapeutics reports Q2 2025 results with narrower-than-expected loss, strong cash reserves, and promising clinical progress in MASH treatment. Stock gains 6.5% pre-market.

AKERO THERAPEUTICS (NASDAQ:AKRO) shows strong technicals with a perfect 10 rating and a high-quality breakout setup, making it a stock to watch for traders.

Jefferies thinks big pharma companies are "still on the hunt" for deals.

The company reportedly hired an investment bank to explore a possible sale.

Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.

In this video lesson, I review the overall market and a new swing position for Monday's session.

Unlike their mega-cap counterparts, which tend to grind, mid-caps can soar or crash within days, driven by headlines and pure speculation.

Check out this week's top-performing mid-cap stocks, including Akero Therapeutics' remarkable 106.57% surge following positive clinical trial results and other companies like Surgery Partners experiencing significant growth due to strategic developments.